Author:
Carrera S.,Buque A.,Azkona E.,Aresti U.,Calvo B.,Sancho A.,Arruti M.,Nuño M.,Rubio I.,de Lobera A. R.,Lopez C.,Vivanco G. L.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference96 articles.
1. Gullick WJ, Downward J, Parker PJ, Whittle N, Kris R, Schlessinger J, et al. The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies. Proc R Soc Lond B Biol Sci. 1985;226(1242):127–34.
2. Lo HW. Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. Discov Med. 2010;10(50):44–51.
3. Zaczek A, Brandt B, Bielawski KP. The diverse signaling of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol. 2005;20(3):1005–15.
4. Normanno N, Maiello MR, De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol. 2003;194(1):13–9.
5. Burris HA 3rd. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol. 2013. doi: 10.1007/s00280-012-2043-3 .
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献